Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

LY6K-AS lncRNA is a lung adenocarcinoma prognostic biomarker and regulator of mitotic progression

ABSTRACT: LY6K-AS lncRNA is a lung adenocarcinoma prognostic biomarker and regulator of mitotic progression

PROVIDER: PRJNA690582 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13380754.fastq.gz	Fastqsanger.gz
	SRR13380755.fastq.gz	Fastqsanger.gz
	SRR13380756.fastq.gz	Fastqsanger.gz
	SRR13380757.fastq.gz	Fastqsanger.gz
	SRR13380758_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

LY6K-AS lncRNA is a lung adenocarcinoma prognostic biomarker and regulator of mitotic progression

Project description:Purpose: Lung adenocarcinoma tumors acquire resistance to the newly-developed as well as existing therapies that restricts life quality improvements. The goal of the current study is to investigate the noncoding portion of the human transcriptome in search of actionable targets for lung adenocarcinoma treatment. Methods: The identified actionable targets (LY6K-AS lncRNA and YWHAG) were transiently downregulated in A549 cell line using either LNA-GapmeRs or siRNA. RNA was extracted from each sample and analyzed in respect to the corresponding control. Results: LY6K-AS lncRNA regulated mitotic progression in A549 cell line through the interaction with YWHAG to orchestrate the expression of several mitosis-promoting factors. Conclusions: Our study indicates that LY6K-AS silencing is a promising therapeutic option for LUAD that inhibits oncogenic mitotic progression.

2021-04-07 | GSE164419 | GEO

Three-lncRNA signature is a potential prognostic biomarker for pancreatic adenocarcinoma.

Project description:Pancreatic adenocarcinoma (PAAD) is a highly aggressive and metastatic cancer characterized by poor survival rates. Long non-coding RNAs (lncRNAs) play important roles in various biological processes, including cancer and PAAD. To identify the specific lncRNAs associated with PAAD and analyze their function, we constructed a global triple network based on the competitive endogenous RNA (ceRNA) theory and RNA-seq data from The Cancer Genome Atlas. Using 182 PAAD cases, we established a lncRNA-miRNA-mRNA co-expression network, which was composed of 43 lncRNA nodes, 253 mRNA nodes, 11 miRNA nodes, and 475 edges. Six lncRNAs in the ceRNA network were closely related to overall survival, and a three-lncRNA signature predicted survival of PAAD patients. Protein-protein interaction network data revealed that five genes were associated with overall survival. These results provide novel insight into the function of a lncRNA-associated ceRNA network in the pathogenesis of PAAD, and indicate that the identified three-lncRNA signature may serve as an independent prognostic marker in PAAD.

| S-EPMC5966255 | biostudies-literature

Circulating miR-181 is a prognostic biomarker for amyotrophic lateral sclerosis

Project description:Circulating miR-181 is a prognostic biomarker for amyotrophic lateral sclerosis

| PRJNA713778 | ENA

Hsa_circ_0066351 acts as a prognostic and immunotherapeutic biomarker in colorectal cancer

Project description:Hsa_circ_0066351 acts as a prognostic and immunotherapeutic biomarker in colorectal cancer

| PRJNA846763 | ENA

Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma

Project description:To evaluate the prognostic relevance of molecular subtypes and key transcription factors in pancreatic ductal adenocarcinoma (PDAC), we performed gene expression analysis of whole-tumor tissue obtained from 118 surgically resected PDAC and 13 control samples.

2016-08-17 | GSE62165 | GEO

The diagnostic and prognostic value of hsa_circ_0084927 in colon adenocarcinoma and its ceRNA network construction (miRNA-Seq)

Project description:Object: This study aims to analyze the differentially expressed circRNA in colon adenocarcinoma (COAD) and evaluate its diagnostic and prognostic value. Establish a new prog

2021-12-06 | GSE189908 | GEO

Development of an immune-related prognostic biomarker for triple-negative breast cancer

Project description:Development of an immune-related prognostic biomarker for triple-negative breast cancer

| PRJEB47208 | ENA

Urinary exosome microRNA signatures as a non-invasive prognostic biomarker for prostate cancer

Project description:Urinary exosome microRNA signatures as a non-invasive prognostic biomarker for prostate cancer

| PRJNA723810 | ENA

Proteomic analyses identify dysregulated proteins and pathways between low-risk and high-risk subtype of early-stage lung adenocarcinoma and their prognostic impacts

Project description:Proteomic analyses identify dysregulated proteins and pathways between low-risk and high-risk subtype of early-stage lung adenocarcinoma and their prognostic impacts.Sample labels: A,low-risk tumor;B,low-risk normal;C,high-risk tumor;D,high-risk normal.

2020-07-18 | MSV000085775 | MassIVE

A Pilot Proteogenomic Study With Data Integration Identifies MCT1 and GLUT1 as Prognostic Markers in Lung Adenocarcinoma

Project description:We performed a pilot proteogenomic study to compare lung adenocarcinoma to lung squamous cell carcinoma using quantitative proteomics (6-plex TMT) combined with a customized Affymetrix GeneChip. Using MaxQuant software, we identified 51,001 unique peptides that mapped to 7,241 unique proteins and from these identified 6,373 genes with matching protein expression for further analysis. We found a minor correlation between gene expression and protein expression; both datasets were able to independently recapitulate known differences between the adenocarcinoma and squamous cell carcinoma subtypes. We found 565 proteins and 629 genes to be differentially expressed between adenocarcinoma and squamous cell carcinoma, with 113 of these consistently differentially expressed at both the gene and protein levels. We then compared our results to published adenocarcinoma versus squamous cell carcinoma proteomic data that we also processed with MaxQuant. We selected two proteins consistently overexpressed in squamous cell carcinoma in all studies, MCT1 (SLC16A1) and GLUT1 (SLC2A1), for further investigation. We found differential expression of these same proteins at the gene level in our study as well as in other public gene expression datasets. These findings combined with survival analysis of public datasets suggest that MCT1 and GLUT1 may be potential prognostic markers in adenocarcinoma and druggable targets in squamous cell carcinoma.

2015-11-06 | PXD002622 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data